Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1978 1
1980 1
1987 1
1988 2
1989 3
1990 4
1991 4
1992 5
1993 6
1994 15
1995 22
1996 22
1997 30
1998 17
1999 12
2000 23
2001 21
2002 14
2003 14
2004 20
2005 26
2006 32
2007 21
2008 15
2009 19
2010 18
2011 16
2012 22
2013 16
2014 16
2015 20
2016 12
2017 14
2018 19
2019 10
2020 11
2021 11
2022 12
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

534 results

Results by year

Filters applied: . Clear all
Page 1
Multiple endocrine neoplasia type 2: A review.
Mathiesen JS, Effraimidis G, Rossing M, Rasmussen ÅK, Hoejberg L, Bastholt L, Godballe C, Oturai P, Feldt-Rasmussen U. Mathiesen JS, et al. Semin Cancer Biol. 2022 Feb;79:163-179. doi: 10.1016/j.semcancer.2021.03.035. Epub 2021 Apr 1. Semin Cancer Biol. 2022. PMID: 33812987 Review.
Multiple endocrine neoplasias are rare hereditary syndromes some of them with malignant potential. Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant hereditary cancer syndrome due to germline variants in the REar
Multiple endocrine neoplasias are rare hereditary syndromes some of them with malignant potential. Multiple endocrin
Phaeochromocytoma.
Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Lenders JW, et al. Lancet. 2005 Aug 20-26;366(9486):665-75. doi: 10.1016/S0140-6736(05)67139-5. Lancet. 2005. PMID: 16112304 Review.
Biochemical testing for phaeochromocytoma is indicated not only in symptomatic patients, but also in patients with adrenal incidentalomas or identified genetic predispositions (eg, multiple endocrine neoplasia type 2, von Hippel-Lindau syndrome, …
Biochemical testing for phaeochromocytoma is indicated not only in symptomatic patients, but also in patients with adrenal incidentalomas or …
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Wells SA Jr, et al. Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335. Thyroid. 2015. PMID: 25810047 Free PMC article. Review.
Management of medullary carcinoma of the thyroid: a review.
Jayasinghe R, Basnayake O, Jayarajah U, Seneviratne S. Jayasinghe R, et al. J Int Med Res. 2022 Jul;50(7):3000605221110698. doi: 10.1177/03000605221110698. J Int Med Res. 2022. PMID: 35822284 Free PMC article. Review.
Although infrequent, the interest in this cancer exceeds its incidence owing to its distinctive features and its characteristic association with other endocrine tumors. Although the majority of MTCs are sporadic, hereditary varieties occur in isolation or as a part of m
Although infrequent, the interest in this cancer exceeds its incidence owing to its distinctive features and its characteristic association …
Therapeutic implications of menin inhibition in acute leukemias.
Issa GC, Ravandi F, DiNardo CD, Jabbour E, Kantarjian HM, Andreeff M. Issa GC, et al. Leukemia. 2021 Sep;35(9):2482-2495. doi: 10.1038/s41375-021-01309-y. Epub 2021 Jun 15. Leukemia. 2021. PMID: 34131281 Review.
Menin inhibitors are novel targeted agents currently in clinical development for the treatment of genetically defined subsets of acute leukemia. Menin has a tumor suppressor function in endocrine glands. Germline mutations in the gene encoding menin cause the multiple
Menin inhibitors are novel targeted agents currently in clinical development for the treatment of genetically defined subsets of acute leuke …
Somatostatin receptors: from signaling to clinical practice.
Theodoropoulou M, Stalla GK. Theodoropoulou M, et al. Front Neuroendocrinol. 2013 Aug;34(3):228-52. doi: 10.1016/j.yfrne.2013.07.005. Epub 2013 Jul 18. Front Neuroendocrinol. 2013. PMID: 23872332 Review.
Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Somatostatin receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protein …
Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological man …
Update on multiple endocrine neoplasia Type 1 and 2.
Al-Salameh A, Baudry C, Cohen R. Al-Salameh A, et al. Presse Med. 2018 Sep;47(9):722-731. doi: 10.1016/j.lpm.2018.03.005. Epub 2018 Jun 13. Presse Med. 2018. PMID: 29909163 Review.
Multiple endocrine neoplasia type 1 is a rare genetic syndrome, characterized by the co-occurrence, in the same individual or in related individuals of the same family, of hyperparathyroidism, duodenopancraetic neuroendocrine tumors, pituitary adenomas
Multiple endocrine neoplasia type 1 is a rare genetic syndrome, characterized by the co-occurrence, in the same
Non-mammalian models of multiple endocrine neoplasia type 2.
Das TK, Cagan RL. Das TK, et al. Endocr Relat Cancer. 2018 Feb;25(2):T91-T104. doi: 10.1530/ERC-17-0411. Endocr Relat Cancer. 2018. PMID: 29348307 Free PMC article. Review.
Twenty-five years ago, RET was identified as the primary driver of multiple endocrine neoplasia type 2 (MEN2) syndrome. MEN2 is characterized by several transformation events including pheochromocytoma, parathyroid adenoma and, especially penetr …
Twenty-five years ago, RET was identified as the primary driver of multiple endocrine neoplasia type 2 (M …
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Fallahi P, et al. Semin Cancer Biol. 2022 Feb;79:180-196. doi: 10.1016/j.semcancer.2020.11.013. Epub 2020 Nov 26. Semin Cancer Biol. 2022. PMID: 33249201 Review.
Pheochromocytomas in Multiple Endocrine Neoplasia Type 2.
Tsang VH, Tacon LJ, Learoyd DL, Robinson BG. Tsang VH, et al. Recent Results Cancer Res. 2015;204:157-78. doi: 10.1007/978-3-319-22542-5_7. Recent Results Cancer Res. 2015. PMID: 26494388 Review.
Over 30% of PCs are associated with germline mutations, including re-arranged in transfection (RET) mutations seen in multiple endocrine neoplasia type 2 (MEN2) syndromes. Around 40% of individuals with MEN2 develop PC, though it is rarely the p …
Over 30% of PCs are associated with germline mutations, including re-arranged in transfection (RET) mutations seen in multiple end
534 results